HomeQuestion
What mutational testing is considered the standard of care for NSCLC?
1 Answers
Mednet Member
Medical Oncology · University of Texas MD Anderson Cancer Center
The easy answer to this question is that the only molecular alterations for which we have matched FDA-approved drugs for those specific indications are EGFR and ALK, so the standard of care would be to test only for EGFR and ALK.
However, over the past 2-3 years, we came to appreciate that several o...